Media Articles Related to Protriptyline
In a rat model of depression, Shuganjieyu capsule increases neurotrophic factor expression
Source: Depression News From Medical News Today [2014.08.23]
Shuganjieyu capsule has been approved for clinical treatment by the State Food and Drug Administration of China since 2008.
Talk Therapy Plus Meds May Be Best for Severe Depression
Source: MedicineNet Depression Specialty [2014.08.22]
Title: Talk Therapy Plus Meds May Be Best for Severe Depression
Category: Health News
Created: 8/21/2014 4:36:00 PM
Last Editorial Review: 8/22/2014 12:00:00 AM
Novel drug to treat respiratory depression helps opioid users breathe easier
Source: Respiratory / Asthma News From Medical News Today [2014.08.21]
People taking prescription opioids to treat moderate to severe pain may be able to breathe a little easier, literally.
Depression in Children
Source: MedicineNet Attention Deficit Hyperactivity Disorder (ADHD) Specialty [2014.08.21]
Title: Depression in Children
Category: Diseases and Conditions
Created: 1/31/2005 4:16:00 AM
Last Editorial Review: 8/21/2014 12:00:00 AM
Combination Therapy Optimizes Recovery in Severe Depression
Source: Latest Plastic Surgery & Aesthetic Medicine Headlines [2014.08.20]
Combination treatment with psychotherapy and antidepressant medication appears to optimize rates of recovery in patients with severe, nonchronic major depression.
Medscape Medical News
Published Studies Related to Protriptyline
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
A daily dose of 20 mg of protriptyline can improve daytime arterial blood gas tensions in chronic obstructive pulmonary disease (COPD)... Despite the low dose, anticholinergic side-effects occurred in most patients.
The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Treatment of nocturnal hypoventilation in patients with restrictive chest wall disease and respiratory failure, results in improved daytime arterial blood gas tensions, increase in functional ability and longer survival. Success has been achieved with the use of protriptyline which reduces the duration of rapid eye movement (REM) sleep during which nocturnal hypoventilation occurs.
Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
A double-blind crossover study was undertaken to assess the effect of protriptyline on ventilatory responses in normal subjects. Seven subjects received in random order placebo, 10 mg and 20 mg protriptyline daily for 2 weeks... Mean HCVR and HVR following 10 mg and 20 mg protriptyline did not differ significantly from measurements on placebo, neither for the single dose study or after 2 weeks.
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or acetazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, and 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome.
Clinical Trials Related to Protriptyline
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to